FDA Accepts Supplement Application for Leflunomide by Barr
The FDA has accepted a supplemental application for Leflunomide submitted by Barr.
Company
Pharmaceutical intelligence for Barr Pharmaceuticals with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.